Comparison · NCT03548454-b3faeeec
Desipramine vs Duloxetine: Adherence
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Desipramine vs Duloxetine: Adherence. Trial comparisons, record NCT03548454-b3faeeec. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03548454-b3faeeec
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.474 | 0.325 | 0.627 | wilson | |
| Risk in group 2 | 0.5 | 0.364 | 0.636 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0263 | -0.228 | 0.179 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.947 | 0.611 | 1.47 | log | |
| Odds ratio, group 1 over group 2 | 0.9 | 0.384 | 2.11 | log | |
| Number needed to treat, for one fewer participant with the outcome on Desipramine than on Duloxetine | 38 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Desipramine | Desipramine starting at 25 mg per day and increasing to 75 mg per day as tolerated. | 18 | 38 | OG000 |
| Group 2 | Duloxetine | Duloxetine starting at 20 mg per day and increasing to 60 mg per day as tolerated. | 24 | 48 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Adherence
- Description
- Number of participants who completed 6-month therapy based on prescription records.
- Time frame
- Monthly for 6 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization
- NCT number
- NCT03548454
- Phases
- PHASE4
- Conditions
- Chronic Pain
- Interventions
- Duloxetine, Desipramine
- Lead sponsor
- Stanford University
- Results first posted
- 2025-11-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03548454?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03548454-b3faeeec